JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.
Acta Haematol
; 144(3): 314-318, 2021.
Article
in English
| MEDLINE | ID: covidwho-691035
ABSTRACT
COVID-19 has rapidly become a major concern for the health systems worldwide. Its high contagiousness and associated mortality demand the discovery of helpful interventions with promising safety profile. Here, we report 3 severe COVID-19 cases, which achieved rapid and sustained improvement in outcome with the use of ruxolitinib, a JAK/STAT pathway inhibitor.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Janus Kinase Inhibitors
/
COVID-19
/
Hematologic Diseases
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
Limits:
Adult
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Acta Haematol
Year:
2021
Document Type:
Article
Affiliation country:
000510179
Similar
MEDLINE
...
LILACS
LIS